The estimated Net Worth of Biomedical Innovation Maste... is at least $27.8 Milión dollars as of 23 June 2020. Biomedical Maste owns over 1,000,000 units of Olema Pharmaceuticals stock worth over $27,800,946 and over the last 5 years Biomedical sold OLMA stock worth over $0.
Biomedical has made over 2 trades of the Olema Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Biomedical bought 1,000,000 units of OLMA stock worth $20,000,000 on 23 June 2020.
The largest trade Biomedical's ever made was buying 1,100,000 units of Olema Pharmaceuticals stock on 16 June 2020 worth over $20,900,000. On average, Biomedical trades about 233,333 units every 1 days since 2020. As of 23 June 2020 Biomedical still owns at least 2,252,913 units of Olema Pharmaceuticals stock.
You can see the complete history of Biomedical Maste stock trades at the bottom of the page.
Biomedical's mailing address filed with the SEC is C/O WELLINGTON MANAGEMENT COMPANY LLP, 280 CONGRESS STREET, BOSTON, MA, 02210.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham a Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: